17.04
+0.77(+4.73%)
Currency In USD
Address
27 West 24th Street
New York, NY 10010
United States of America
Phone
646-481-9832
Sector
Healthcare
Industry
Biotechnology
Employees
74
First IPO Date
May 07, 2021
| Name | Title | Pay | Year Born |
| Dr. Kevin B. Johnson M.B.A., Ph.D. | Chief Regulatory Officer | 555,835 | 1964 |
| Ms. Dora Rau | Senior Vice President & Head of Quality | 0 | N/A |
| Mr. Ryan Robinson CPA | Chief Financial Officer & Treasurer | 0 | 1988 |
| Mr. W. Bradford Middlekauff J.D. | Chief Business Officer, General Counsel & Corporate Secretary | 0 | 1962 |
| Dr. John Walsh M.D. | Vice President & Head of Medical Affairs | 0 | N/A |
| Dr. Susan Dana Jones Ph.D. | Chief Technology Officer | 0 | 1960 |
| Mr. Gerhard Hagn Pharm.D. | Senior Vice President and Head of Commercial & Business Development | 0 | N/A |
| Dr. Emil M. deGoma M.D. | Senior Vice President of Medical Research | 0 | N/A |
| Ms. Kimberly Piorkowski | Vice President of People, Culture & Compliance | 0 | N/A |
| Dr. Kristine Erickson O.D., Ph.D. | Vice President & TA Head of Ophthalmology, Medical Research | 0 | N/A |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.